{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Ma J"],"pubmed_abstract":["<h4>Background</h4>We aimed to report our clinical experience with the use of <sup>225</sup>Ac-PSMA-617 in the treatment of mCRPC patients.<h4>Methods</h4>A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with <sup>225</sup>Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired <sup>68</sup>Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effect"],"journal":["Frontiers in oncology"],"pagination":["1516860"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11906306"],"repository":["biostudies-literature"],"pubmed_title":["The efficacy and safety of &lt;sup&gt;225&lt;/sup&gt;Ac-PSMA-617 in metastatic castration-resistant prostate cancer."],"pmcid":["PMC11906306"],"pubmed_authors":["Yangqing J","Zhang Y","Ma J","Zhang C","Wang J","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"The efficacy and safety of &lt;sup&gt;225&lt;/sup&gt;Ac-PSMA-617 in metastatic castration-resistant prostate cancer.","description":"<h4>Background</h4>We aimed to report our clinical experience with the use of <sup>225</sup>Ac-PSMA-617 in the treatment of mCRPC patients.<h4>Methods</h4>A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with <sup>225</sup>Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired <sup>68</sup>Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effect","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-04-04T14:48:08.716Z","creation":"2025-04-04T14:48:08.716Z"},"accession":"S-EPMC11906306","cross_references":{"pubmed":["40094004"],"doi":["10.3389/fonc.2025.1516860"]}}